Oncology & Cancer

Tailoring lung cancer therapies to individual patients

Recent findings in the laboratory of University of Kentucky Markey Cancer Center researcher Christine Brainson, Ph.D., could lead to promising treatments for two molecular subtypes of lung cancer.

Oncology & Cancer

Researchers develop new generation tumor-specific pro-IL-12

Interleukin-12 (IL-12), a potent inducer of cell-mediated immunity, can stimulate the anti-tumor effector functions of the activated T and NK cells for solid tumors rejection. However, clinical administration of IL-12 has ...

Medications

Potential combined drug therapy for lung cancer

Most lung cancers are of a type called non-small-cell lung carcinoma (NSCLC). This type of cancer is relatively insensitive to chemotherapy, so NSCLC therapies are usually based on drug treatment. Alectinib is a drug commonly ...

page 1 from 16